By Elaine Rigoli
Tampa, Fla., July 13 - Protiva Biotherapeutics, Inc. announced the completion of a convertible debenture financing with commitments of C$5.6 million. This third round of financing brings Protiva's cumulative venture capital financing to C$26 million.
The investment was completed with full participation from existing Protiva investors, including the following institutional investors: the Working Opportunity Fund managed by GrowthWorks Capital, BDC Capital, the Canadian Medical Discoveries Fund and Kinetic Capital.
Protiva said it will use the funds to advance its ongoing work developing its proprietary stable nucleic-acid lipid particle technology.
Vancouver, B.C.-based Protiva is a development-stage biotechnology company.
| Issuer: | Protiva Biotherapeutics, Inc.
|
| Issue: | Convertible debt financing
|
| Amount: | C$5.6 million
|
| Investors: | The Working Opportunity Fund managed by GrowthWorks Capital, BDC Capital, the Canadian Medical Discoveries Fund and Kinetic Capital
|
| Announcement date: | July 13
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
